Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

Joyce F. Liu, MD, MPH


Medical Oncology

Make an Appointment

Physician

  • Associate Chief, Division of Gynecologic Oncology
  • Director of Clinical Research, Division of Gynecologic Oncology
  • Physician
  • Assistant Professor of Medicine, Harvard Medical School

Centers/Programs

Clinical Interests

  • Gynecologic malignancies
  • Targeted Therapy

Contact Information

  • Appointments617-632-2175
  • Office Phone Number617-632-5269
  • Fax617-632-3479

Bio

Dr. Liu received her medical degree from Harvard Medical School in 2002. She completed her residency in Internal Medicine at Brigham and Women's Hospital, and her fellowship in Hematology Oncology at the Dana-Farber Cancer Institute. In 2008, she joined the staff of Dana-Farber and Brigham and Women's Hospital, where she is a medical oncologist and clinical investigator in the Division of Gynecologic Oncology. Her research focuses on identifying and validating potential therapeutic targets in advanced platinum-resistant ovarian cancer, in an in-vitro setting as well as in a murine xenograft model of ovarian cancer. Dr. Liu is also active in conducting clinical research directed towards developing a better understanding of the basic biology of ovarian cancer and translating discoveries from the laboratory into the clinical setting.

Fellowship:

  • Dana-Farber/Partners CancerCare, Medical Oncology

Residency:

  • Brigham and Women's Hospital, Internal Medicine

Medical School:

  • Harvard Medical School

Research

Enhanced Efficacy of Aurora Kinase Inhibitors in G2/M Checkpoint Deficient TP53 Mutant Uterine Carcinomas Is Linked to the Summation of LKB1-AKT-p53 Interactions. Cancers (Basel). 2021 May 03; 13(9).
View in: PubMed

Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma. J Clin Oncol. 2021 May 10; 39(14):1531-1539.
View in: PubMed

Stepping into survivorship pilot study: Harnessing mobile health and principles of behavioral economics to increase physical activity in ovarian cancer survivors. Gynecol Oncol. 2021 May; 161(2):581-586.
View in: PubMed

Lived experiences of women reporting fatigue during PARP inhibitor maintenance treatment for advanced ovarian cancer: A qualitative study. Gynecol Oncol. 2021 01; 160(1):227-233.
View in: PubMed

Uterine serous carcinoma: Molecular features, clinical management, and new and future therapies. Gynecol Oncol. 2021 01; 160(1):322-332.
View in: PubMed

Clinical assays for assessment of homologous recombination DNA repair deficiency. Gynecol Oncol. 2020 12; 159(3):887-898.
View in: PubMed

Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial. Gynecol Oncol. 2020 10; 159(1):72-78.
View in: PubMed

A single-cell landscape of high-grade serous ovarian cancer. Nat Med. 2020 08; 26(8):1271-1279.
View in: PubMed

Genomic Determinants of De Novo Resistance to Immune Checkpoint Blockade in Mismatch Repair-Deficient Endometrial Cancer. JCO Precis Oncol. 2020; 4:492-497.
View in: PubMed

Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035). Gynecol Oncol Rep. 2020 May; 32:100546.
View in: PubMed

Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline. J Clin Oncol. 2020 04 10; 38(11):1222-1245.
View in: PubMed

Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer. Ann Oncol. 2019 Apr; 30(4):551-557.
View in: PubMed

Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial. JAMA Oncol. 2019 12 01; 5(12):1731-1738.
View in: PubMed

Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations. Gynecol Oncol. 2020 02; 156(2):488-497.
View in: PubMed

Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer. J Clin Oncol. 2019 10 20; 37(30):2786-2794.
View in: PubMed

The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition. Clin Cancer Res. 2019 10 15; 25(20):6127-6140.
View in: PubMed

Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer. Gynecol Oncol Rep. 2019 Aug; 29:118-122.
View in: PubMed

Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers. Gynecol Oncol. 2019 08; 154(2):314-322.
View in: PubMed

Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer. Gynecol Oncol. 2019 07; 154(1):95-101.
View in: PubMed

Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC). Int J Gynecol Pathol. 2019 May; 38(3):230-240.
View in: PubMed

Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer. Ann Oncol. 2019 04 01; 30(4):551-557.
View in: PubMed

Antibody-drug conjugates in gynecologic malignancies. Gynecol Oncol. 2019 06; 153(3):694-702.
View in: PubMed

Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient-Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness. Mol Cancer Ther. 2019 03; 18(3):642-655.
View in: PubMed

PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer. Cell Rep. 2018 12 11; 25(11):2972-2980.e5.
View in: PubMed

Technology Applications: Use of Digital Health Technology to Enable Drug Development. JCO Clin Cancer Inform. 2018 12; 2:1-12.
View in: PubMed

Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13. Elife. 2018 11 13; 7.
View in: PubMed

Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids. Cancer Discov. 2018 11; 8(11):1404-1421.
View in: PubMed

Epigenetic Reprogramming Strategies to Reverse Global Loss of 5-Hydroxymethylcytosine, a Prognostic Factor for Poor Survival in High-grade Serous Ovarian Cancer. Clin Cancer Res. 2018 03 15; 24(6):1389-1401.
View in: PubMed

Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response. Nat Commun. 2017 08 28; 8(1):365.
View in: PubMed

Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer. Ann Oncol. 2016 11; 27(11):2124-2130.
View in: PubMed

Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer. J Clin Oncol. 2016 12 20; 34(36):4345-4353.
View in: PubMed

Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics. Clin Cancer Res. 2017 Mar 01; 23(5):1263-1273.
View in: PubMed

What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment? Curr Oncol Rep. 2016 May; 18(5):29.
View in: PubMed

Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget. 2016 Mar 22; 7(12):13587-98.
View in: PubMed

Development of a prosaposin-derived therapeutic cyclic peptide that targets ovarian cancer via the tumor microenvironment. Sci Transl Med. 2016 Mar 09; 8(329):329ra34.
View in: PubMed

Anti-CCR4 monoclonal antibody enhances antitumor immunity by modulating tumor-infiltrating Tregs in an ovarian cancer xenograft humanized mouse model. Oncoimmunology. 2016 Mar; 5(3):e1090075.
View in: PubMed

Bevacizumab in newly diagnosed ovarian cancer. Lancet Oncol. 2015 Aug; 16(8):876-8.
View in: PubMed

An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma. Proc Natl Acad Sci U S A. 2015 Jan 06; 112(1):232-7.
View in: PubMed

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol. 2014 Oct; 15(11):1207-14.
View in: PubMed

Emerging role for bevacizumab in combination with chemotherapy for patients with platinum-resistant ovarian cancer. J Clin Oncol. 2014 May 01; 32(13):1287-9.
View in: PubMed

PARP inhibitors in ovarian cancer: current status and future promise. Gynecol Oncol. 2014 May; 133(2):362-9.
View in: PubMed

In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene. Proc Natl Acad Sci U S A. 2014 Jan 21; 111(3):1102-7.
View in: PubMed

Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers. Cancer Res. 2014 Feb 15; 74(4):1141-52.
View in: PubMed

Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance. Proc Natl Acad Sci U S A. 2013 Oct 15; 110(42):17041-6.
View in: PubMed

Predictive value of circulating tumor cells (CTCs) in newly-diagnosed and recurrent ovarian cancer patients. Gynecol Oncol. 2013 Nov; 131(2):352-6.
View in: PubMed

A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. Eur J Cancer. 2013 Sep; 49(14):2972-8.
View in: PubMed

Anti-angiogenic agents in ovarian cancer: dawn of a new era? Curr Oncol Rep. 2011 Dec; 13(6):450-8.
View in: PubMed

Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas. Gynecol Oncol. 2011 Oct; 123(1):5-12.
View in: PubMed

Poly ADP-ribose polymerase inhibitors: science and current clinical development. Curr Opin Oncol. 2010 Nov; 22(6):567-72.
View in: PubMed

An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell. 2010 Mar 16; 17(3):298-310.
View in: PubMed

Prognosis and hormone receptor status in older and younger patients with advanced-stage papillary serous ovarian carcinoma. Gynecol Oncol. 2009 Dec; 115(3):401-6.
View in: PubMed

Notch1 and Notch3 Overexpression in Young Women with Papillary Serous Ovarian Carcinoma. USCAP 97th Annual Meeting. 2008; Abst #1448.

The Metastasis-Associated Protein 1 (MTA1) is a Prognostic Biomarker in Papillary Serous Ovarian Carcinoma. USCAP 97th Annual Meeting. 2008; Abst #1447.

Epithelial Ovarian Cancer. 2007.

Protein expression and clinical features of ovarian cancer in the elderly. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part 1. 2007; 25(18S):5574.

ErbB3 protein expression in serous ovarian carcinomas of elderly women. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part 1. 2007; 25(18S):16026.

Treatment of advanced ovarian cancer. Touch Briefings. 2006.

Rational use of cytotoxic chemotherapy for recurrent ovarian cancer. J Natl Compr Canc Netw. 2006 Oct; 4(9):947-53.
View in: PubMed

End-of-Life Care. Treatment and Management of Cancer in the Elderly. Ed: Hyman Muss, Carrie Hunter, Karen Johnson. 2006; 559-586.

Interns' work hours. N Engl J Med. 2005 Feb 17; 352(7):726-8; author reply 726-8.
View in: PubMed

CD40 activation of carcinoma cells increases expression of adhesion and major histocompatibility molecules but fails to induce either CD80/CD86 expression or T cell alloreactivity. Int J Oncol. 2001 Oct; 19(4):791-8.
View in: PubMed

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215
Get Directions

Dana-Farber Cancer Institute - Chestnut Hill
300 Boylston Street
Newton, MA 02459
Get Directions

Ratings

Top